Gegechkori N, et al. - Researchers examined how bisphosphonate use—defined as the presence of ≥ 1 pharmacy claim from 6 months prior to cancer diagnosis to the incident cardiovascular disease (CVD) event—influences the rates of incident CVD events among early-stage breast cancer survivors. Using data from the Surveillance, Epidemiology and End Results registry linked to Medicare claims, they identified a total of 2,178 breast cancer survivors who had ≥ 1 bisphosphonate prescription; the average length of bisphosphonate use was 15 months. Using propensity scores, they created a matched group of breast cancer survivors without bisphosphonate exposure. The analysis revealed a significant association of bisphosphonate use with fewer incident CVD events among older early-stage breast cancer survivors